Maddys

Generic drugs market growth is buoyed by increasing number of patented expiries for drugs each year. According to the IMS data small-molecule products worth US$ 121 Bn are expected to lose patents in developed markets, such as U.S and Europe between 2014 and 2018. The IMS also forecasts that biologic products valued at US$ 48 Bn are expected to lose patent protection over the next three years i.e from 2017 and 2020, which is expected to drive growth of the generic drugs market. Global generics market is highly competitive with many Asia Pacific companies entering the developed markets such as the U.S., Germany, France, and UK. Recent past has witnessed spurt in mergers and acquisitions between generic drug manufacturers, with major players focusing on enhancing their product portfolio through such inorganic strategies. For instance, Teva Pharmaceutical Industries Pvt. Ltd., Pfizer, Inc., Mylan, Sun Pharmaceutical, and Fresenius Kabi entered into acquisitions to increase their rev

Biomarkers are used for diagnosis and drug development, as these biomarkers can indicate diseases in the body. Furthermore, biomarkers can be any specific cells, molecules, genes or gene products, enzymes or hormones. Biomarker-based test are precise and rapid, which help in early prediction of susceptibility, prognosis, diagnosis, and treatment of disease. Hence, increasing research and development activities for identifying new biomarkers to diagnose or treat diseases is expected to be major factor growth of the market. Biomarker are required for personalized medicine as it helps to identify the unique characteristics of the disease and helps to tailor medicine according to the need of patients. Hence, to cater to demand for personalized medicines, pharmaceutical companies are investing in R&D, which is expected to lead to identification of novel biomarkers, thus aiding in growth of the market. Request Sample Copy Of This Research Report: https://www.coherentmarketins

Cardiovascular information system is a web-based solution that provides an end-to-end management platform and allows cardiologists and clinical staff to efficiently access post-procedural phases of patient care, including imaging, reporting, hemodynamics, analytics, and others. McKesson Cardiology streamlines data management into a single Cardiovascular Information System (CVIS), which allows to collect data and help improve the quality of care provided to patients. Market Dynamics Continuous advancement of the database modules within the CVIS that covers the entire spectrum of cardiovascular activities, including both invasive and non-invasive is expected to propel growth of the market over the forecast period. Furthermore, increasing imaging and diagnostic tests in various regions are expected to drive growth of cardiovascular information system market. For instance, according to the National Health Service, England, 39.8 million imaging tests were reported in England in

The patient-tailored therapies for the treatment of variety of disease are known as personalized cell therapy. The personalized cell therapy is based on genomic profile, and disease prevalence/severity and the drug developed by this therapy target the patients who matches the specific disease physiopathology and/or patient characteristics. The personalized cell therapy is mainly developed for the treatment of high unmet need disease such as cancer, also it comprises drugs for treatment of other diseases such as autoimmune disease, cardiovascular, neurologic and inflammatory disease. Personalized cell therapy also finds application in the area of platelet transfusions, packed red cell transfusions, bone marrow transplantation and in organ transplantation. Request For Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/204 Personalized Cell Therapy Market Dynamics The continuous development in science and technology sec